Recent

% | $
Quotes you view appear here for quick access.

Novadaq Technologies Inc. Message Board

andersongordon 78 posts  |  Last Activity: Mar 29, 2015 12:18 AM Member since: Jul 11, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • andersongordon@ymail.com andersongordon Jan 12, 2015 3:28 PM Flag

    Jay why do you say it is a joke? The technology is effective and proven. It is cost beneficial in that it not only provides guidance to surgeons in making decisions on treatment and surgeries but it saves repair and the subsequent legal costs. The $6.00 stock estimate is based on what? I see the price higher than would be demanded from the current revenue and market penetration, but this is a new technology / service and will need time to penetrate the medical community. I ask in all sincerity. I am an investor and am always open to views and insights other than mine for re-evaluation.

    Thanks in advance
    GSA

  • Reply to

    current weakness

    by vonpezel Jan 7, 2015 11:26 AM
    andersongordon@ymail.com andersongordon Jan 12, 2015 2:16 PM Flag

    and = an

  • Reply to

    current weakness

    by vonpezel Jan 7, 2015 11:26 AM
    andersongordon@ymail.com andersongordon Jan 12, 2015 2:15 PM Flag

    Very good. Are you and English major, editor or proofer?

    Remember "What's My Line"?

    Gene Francis

  • I assume the new training video is with the newly upgraded product. It has "fool proof" aspects that make the newly designed tool and staples very easy to use and the surgeon's guess work about whether the staple is the right one has been removed. If the tissue is too thick for the staple size the tool will not let the stapling proceed. The reloading procedure and staple clip removing and inserting aids make it so simple even I could do it just watching the video. I like where they are going with this, it only remains for the next larger size staples to be approved with the tools needed and Cardica will have a true suite of stapler-cutters to offer that have advanced, easy to use, robust options now not existent in the operation theater.

    Has anyone any anecdotal information on how the upgrade is being accepted in the field?

    GSA

  • The surprise lower Q4 earnings according to Arun was due to the significant drop in capital sales from LifeCell. Now that this product has been brought back into the NVDQ fold, I expect there will be a ramp up time of a year or so. Remember the agreement was that no sales personnel would be taken by NVDQ for 1 year. This is a blow to the contacts established though will be transient in nature. He did say that the PINPOINT and LUNA sales for Q4 exceeded their expectations. If NVDQ received ~$125k of the ~$250k sale price from LifeCell, then there would have been at least 16 sales that were not made that were expected, perhaps even more if the PINPOINT and LUNA sales were greater than anticipated. I see this as a transient and not a change in the fundamentals for Novadaq. I expect the market to be shortsighted and the short sellers may be in charge, at least until tomorrows Analyst Day when Arun will have the opportunity to explain the strategic and tactical response and anticipated results.

    GSA

  • Why didn't the stock drop? Someone sold 180k shares this morning which drove the price down to $0.68 from $0.72 but it came back up to $0.72 shortly thereafter. This tells me that someone still sees value in Cardica and is willing to purchase i.e. accumulate shares. They have been doing it for days now, first at $0.68@ then $0.70@ and today at $0.72@. They have purchased it around 100 shares or 300 shares on a semi-random routine around one to three times a minute. Doing this does not drive up the price and yet at the end of the day they have accumulated 30k-80k shares day after day. If this is Broadfin, then they could be building a supply for the eventual sale to the takeover bidder (J&J or Applied or ?). Someone is taking the position that could pay 40%-200% return in a year if there is a decent buyout offer.

    Any thoughts? All welcome to offer other theories.

    GSA

  • andersongordon@ymail.com andersongordon Jan 9, 2015 11:00 AM Flag

    Gene: there is an ominus #10.
    Bryan either falsified results/records of failed to disclose a weakness or flaw in the design. If this is the reason he was so summarily terminated I would expect the management and BOD is currently in full damage control mode and there would be a "blackout" until they have developed a strategic and tactical approach to remedy the situation. If they had slack cash resources to ride it out, this scenario would be serious but not fatal. In Cardica's case it may be worse than serious...

    I wait to hear from Cardica, but I don't like the fact that their web site is down...

    GSA

  • Why, anyone have any information on this?

    GSA

  • Reply to

    current weakness

    by vonpezel Jan 7, 2015 11:26 AM
    andersongordon@ymail.com andersongordon Jan 7, 2015 5:54 PM Flag

    Thanks Von, that's how I see it too. If I come up with something I'll post it.

    GSA

  • andersongordon@ymail.com andersongordon Jan 7, 2015 4:13 PM Flag

    No, not in 2015. There were 14 Democrats who voted for the repeal or at least were said to favor it. There are now 54 Republicans. That's the needed 67. Just one problem, 10 of those 14 are no longer in the Senate. The remaining 44 Democratic Senators are even more left leaning than the 58 were last year. In addition this is going to the sacred cow of the President and his supporters, hence not very likely they will break from a Presidents veto.

    However, 2016 is a different story and the Medical Device bill will be brought up again dressed as a high paying jobs bill for the US medical equipment and manufacturing industries. I suspect of the 16 Senators up for vote there will be 6-8 who may not want to fall on the sword for a departing President.

    GSA

  • Reply to

    current weakness

    by vonpezel Jan 7, 2015 11:26 AM
    andersongordon@ymail.com andersongordon Jan 7, 2015 1:50 PM Flag

    Pinpoint Commercial Pricing:
    Statement by Arun 12/04/13:
    1)"Based on pricing study with hospitals we will set the price between $100k and $125k."
    2)"We are currently in the 30 teaching hospitals and have the current goal to penetrate the top 100 hospitals 'fast'. Eventually we expect 1,000 hospitals to have our machines with each having ~6 operating rooms. US market potential is ~10,000 placements"

    If there is no pre-earnings warning then in order to meet the "40% revenue growth or 2014" stated goal will require $15,450,000 revenue this quarter. That translates to a loss of $0.05 per share. The analyst consensus is a loss of $0.09 per share. Based on Arun's "very confident" we will meet the revenue forecasted, statements in his recent presentations, I think we are in for a big day on the 14th of January. I expect there will be a comment not only about the 2014 projection but an increase of it for 2015. As for the stock "slide" the price has not moved at all for 2014. Started at $16.31 ended at the same place. Some institutions may want to remove "non-performers" and build cash as the risks to the market increase and the future "downturn" comes ever closer.

    GSA

  • Reply to

    current weakness

    by vonpezel Jan 7, 2015 11:26 AM
    andersongordon@ymail.com andersongordon Jan 7, 2015 11:37 AM Flag

    Von, have you found any way to check progress on Novadaq equipment placements? ISRG has a web site listing doctors and hospitals with their machines which can be monitored, but I have found nothing even anecdotal that helps in judging NVDQ's marketing progress.

    Any ideas?

    GSA

  • Reply to

    Many unanswered questions

    by gene_ramirez_vox Jan 2, 2015 11:02 AM
    andersongordon@ymail.com andersongordon Jan 3, 2015 11:25 AM Flag

    Love your out of the box thinking. Bring the surgical community into it too. Give options for identifying improvement/wish lists and suggestions to implement them.

    GSA

  • andersongordon@ymail.com andersongordon Jan 2, 2015 12:20 PM Flag

    3.2% dividend yield vs 2.4% for government bonds and a triple A rating vs double A with return to $90-$100 per barrel oil predicted by Saudi Arabia as growth of demands continues (even though tepid) and natural depletion of existing wells of 6% per year are not matched by the new lower drilling rate...for those who want to hold a cash stream delivering asset, Exxon is the best bet in town.

    GSA

  • Reply to

    Many unanswered questions

    by gene_ramirez_vox Jan 2, 2015 11:02 AM
    andersongordon@ymail.com andersongordon Jan 2, 2015 11:54 AM Flag

    I would like to see Dr. Hansen become the Chief Technology Officer, which would include equipment, R&D, and statistical studies. Give him a good incentive, (options worthy of his founding father genius) and bring in a business CEO with acumen in medical equipment.

    GSA

  • Reply to

    Many unanswered questions

    by gene_ramirez_vox Jan 2, 2015 11:02 AM
    andersongordon@ymail.com andersongordon Jan 2, 2015 11:38 AM Flag

    Good questions Gene. Please send them to Cardica for them to address in their next general presentation.

    GSA

  • Reply to

    SIX WEEKS AND NOT A PEEP FROM CRDC

    by tickedoffinvestor Dec 29, 2014 12:11 PM
    andersongordon@ymail.com andersongordon Jan 1, 2015 6:51 PM Flag

    That's not true Mojo. I have had a few conversations with those you mentioned above, all very professional, very courteous and very serious about making Cardica a success.

    GSA

  • Reply to

    SIX WEEKS AND NOT A PEEP FROM CRDC

    by tickedoffinvestor Dec 29, 2014 12:11 PM
    andersongordon@ymail.com andersongordon Dec 31, 2014 9:57 AM Flag

    Good points Gene.

    GSA

NVDQ
15.92+0.59(+3.85%)1:29 PMEDT